217 related articles for article (PubMed ID: 10630360)
1. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
3. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia.
Ferrao P; Sincock P; Cole S; Ashman L
Leuk Res; 2001 May; 25(5):395-405. PubMed ID: 11301107
[TBL] [Abstract][Full Text] [Related]
4. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
6. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
7. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
8. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
Michieli M; Damiani D; Ermacora A; Masolini P; Michelutti A; Michelutti T; Russo D; Pea F; Baccarani M
Br J Haematol; 1999 Jul; 106(1):92-9. PubMed ID: 10444168
[TBL] [Abstract][Full Text] [Related]
9. Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.
Cheng J; Wu W; Chen BA; Gao F; Xu W; Gao C; Ding J; Sun Y; Song H; Bao W; Sun X; Xu C; Chen W; Chen N; Liu L; Xia G; Li X; Wang X
Int J Nanomedicine; 2009; 4():209-16. PubMed ID: 19918367
[TBL] [Abstract][Full Text] [Related]
10. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin.
Cheng J; Wang J; Chen B; Xia G; Cai X; Liu R; Ren Y; Bao W; Wang X
Int J Nanomedicine; 2011; 6():2123-31. PubMed ID: 22114476
[TBL] [Abstract][Full Text] [Related]
11. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
12. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
[TBL] [Abstract][Full Text] [Related]
13. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
14. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.
Hurwitz SJ; Terashima M; Mizunuma N; Slapak CA
Blood; 1997 May; 89(10):3745-54. PubMed ID: 9160680
[TBL] [Abstract][Full Text] [Related]
15. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
[TBL] [Abstract][Full Text] [Related]
17. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
Xu DH; Gao JQ; Liang WQ
Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
[TBL] [Abstract][Full Text] [Related]
18. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
19. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Chauvier D; Morjani H; Manfait M
Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
[TBL] [Abstract][Full Text] [Related]
20. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
